-
Merck KGaA Completes Acquisition of HUB Organoids, Expanding Cell Culture Portfolio
•
German major Merck KGaA (ETR: MRK) announced the completion of its acquisition of Holland-based HUB Organoids Holding B.V. (HUB) last month, following regulatory approval and the fulfillment of other customary transaction conditions. The deal was initially revealed on December 17, 2024. Significance of the AcquisitionHUB is a pioneer in the…
-
Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development
•
Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids Holding B.V. (HUB), a company specializing in organoid technology. Organoids, which are cell culture models that functionally resemble organs, hold the potential to revolutionize drug development by accelerating processes, enhancing disease treatment understanding across diverse…
